09/02/2026
Approximately 85% of ALS cases are sporadic, yet most laboratory models represent genetic forms of the disease. To better understand sporadic ALS and develop potential treatments, researchers need models that more accurately reflect its biology and diversity.
PRISM ALS was created to help meet this need. ALS TDI, LifeArc, and Axol Bioscience Ltd. are developing a shared panel of patient-derived motor neuron models representing sporadic ALS, benchmarking them against familial ALS lines, and making them available to researchers and companies across the field.
Watch the full ALS Town Hall to learn how PRISM ALS is building better tools to accelerate ALS research: https://www.als.net/als-town-hall/archive/07232026/